MSLN, a tumor-associated antigen, is a clinically validated target for immunotherapy and other treatment strategies for PC, mesothelioma, and ovarian cancer, including immunotoxins, vaccines, chimeric monoclonal Abs, Ab-drug conjugates, and chimeric antigen receptor (CAR) T-cell therapy [72]. The gene discussed is MSLN; the disease is mesothelioma.